Alfacalcidol (One-Alpha) cap 0.25mg: Supply issue

Supply issue Active

Due to an increase in demand, Alfacalcidol (One-Alpha) cap 0.25mg is out of stock (Pharmacode 203084)

Supply status

Due to an increase in demand, alfacalcidol (One-Alpha) cap 0.25mg is out of stock (Pharmacode 203084). 

An alternative Section 29 alfacalcidol product was listed from 11 April. It is due to arrive in late-April.

There may be a brief period where there is no stock of alfacalcidol available, please plan accordingly. 

Affected product

  • Chemical: Alfacalcidol
  • Presentation: Cap 0.25 mcg
  • Brand: One-Alpha
  • Pharmacode: 203084
  • Subsidy: $26.32
  • Measure / Qty: per 100

Schedule listing for alfacalcidol(external link)

Alternative product

We have listed an alternative brand and expect it to be available in late-April. 

  • Chemical: Alfacalcidol
  • Presentation: Cap 0.25 mcg
  • Pharmacode: 2677954
  • Subsidy: $26.32
  • Measure / Qty: per 100
  • List date: 11 April 2024

The alternative product is supplied under Section 29, wastage rules apply.

Once this Section 29 product has arrived, there will be enough stock of it to last until the registered brand returns. 

Prescribing and supplying an unapproved medicine

Section 29 of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as, a doctor. 

We know supplying a medicine under section 29 is not ideal. In this case, however, this will allow patients to be able to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Advice for prescribing under section 29 – BPAC website(external link)(external link) 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website (external link)(external link)

Medsafe’s section 29 Declaration / Notification Form [DOC](external link)(external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Expected resupply 

Normal supply is expected to resume by July 2024.

Who to contact

If you have questions about this issue, email

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.  

Sign up to our email list for regular emails about supply issues and more(external link)